Literature DB >> 1669525

Trials of hypertension prevention. Phase I design.

S Satterfield1, J A Cutler, H G Langford, W B Applegate, N O Borhani, E Brittain, J D Cohen, L H Kuller, N L Lasser, A Oberman.   

Abstract

Phase I of the Trials of Hypertension Prevention (TOHP) was a National Heart, Lung, and Blood Institute-sponsored, 3-year, national, multicenter, randomized, controlled trial designed to test the feasibility and efficacy of three life-style (weight loss, sodium restriction, and stress management) and four nutrition supplement (calcium, magnesium, fish oil, and potassium) interventions aimed at lowering diastolic blood pressure in those whose blood pressure was initially in the high normal range (80 to 89 mm Hg). A total of 2182 volunteers were recruited and allocated to the various treatment arms, such that each hypothesis was tested with a power of 85% or higher to detect a diastolic blood pressure treatment effect of 2 mm Hg. The four nutrition supplement interventions were delivered in a double-blinded fashion and the three life-style interventions, single (observed) -blinded. Phase I was designed to provide a rigorous test of short-term lowering of blood pressure for each of the seven treatments chosen and provides the basis for planning of a subsequent long-term trial of hypertension prevention.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1669525     DOI: 10.1016/1047-2797(91)90014-4

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  14 in total

Review 1.  Reduced or modified dietary fat for preventing cardiovascular disease.

Authors:  Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen J Moore; George Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  The transitioning from trials to extended follow-up studies.

Authors:  Lea T Drye; Anne S Casper; Alice L Sternberg; Janet T Holbrook; Gabrielle Jenkins; Curtis L Meinert
Journal:  Clin Trials       Date:  2014-08-12       Impact factor: 2.486

3.  Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study.

Authors:  Nancy R Cook; Eva Obarzanek; Jeffrey A Cutler; Julie E Buring; Kathryn M Rexrode; Shiriki K Kumanyika; Lawrence J Appel; Paul K Whelton
Journal:  Arch Intern Med       Date:  2009-01-12

4.  Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP).

Authors:  Nancy R Cook; Jeffrey A Cutler; Eva Obarzanek; Julie E Buring; Kathryn M Rexrode; Shiriki K Kumanyika; Lawrence J Appel; Paul K Whelton
Journal:  BMJ       Date:  2007-04-20

Review 5.  Reduced or modified dietary fat for preventing cardiovascular disease.

Authors:  Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen Moore; George Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

6.  Reduction in saturated fat intake for cardiovascular disease.

Authors:  Lee Hooper; Nicole Martin; Oluseyi F Jimoh; Christian Kirk; Eve Foster; Asmaa S Abdelhamid
Journal:  Cochrane Database Syst Rev       Date:  2020-08-21

7.  Effects of total fat intake on body fatness in adults.

Authors:  Lee Hooper; Asmaa S Abdelhamid; Oluseyi F Jimoh; Diane Bunn; C Murray Skeaff
Journal:  Cochrane Database Syst Rev       Date:  2020-06-01

8.  Reduction in saturated fat intake for cardiovascular disease.

Authors:  Lee Hooper; Nicole Martin; Oluseyi F Jimoh; Christian Kirk; Eve Foster; Asmaa S Abdelhamid
Journal:  Cochrane Database Syst Rev       Date:  2020-05-19

9.  Plasma renin activity is associated with bone mineral density in premenopausal women.

Authors:  F A Tylavsky; K C Johnson; J Y Wan; G Harshfield
Journal:  Osteoporos Int       Date:  1998       Impact factor: 5.071

10.  Twenty-Four-Hour Diet recall and Diet records compared with 24-hour urinary excretion to predict an individual's sodium consumption: A Systematic Review.

Authors:  Rachael M McLean; Victoria L Farmer; Alice Nettleton; Claire M Cameron; Nancy R Cook; Mark Woodward; Norman R C Campbell
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-10-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.